Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Total Liabilities (2016 - 2026)

Rhythm Pharmaceuticals has reported Total Liabilities over the past 10 years, most recently at $210.2 million for Q4 2025.

  • Quarterly Total Liabilities fell 7.71% to $210.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $210.2 million through Dec 2025, down 7.71% year-over-year, with the annual reading at $210.2 million for FY2025, 7.71% down from the prior year.
  • Total Liabilities was $210.2 million for Q4 2025 at Rhythm Pharmaceuticals, roughly flat from $211.2 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $239.2 million in Q2 2025 and troughed at $33.6 million in Q3 2021.
  • The 5-year median for Total Liabilities is $142.2 million (2023), against an average of $140.5 million.
  • Year-over-year, Total Liabilities surged 223.06% in 2022 and then decreased 7.71% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $45.4 million in 2021, then surged by 160.55% to $118.2 million in 2022, then soared by 37.87% to $163.0 million in 2023, then soared by 39.72% to $227.7 million in 2024, then fell by 7.71% to $210.2 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Total Liabilities are $210.2 million (Q4 2025), $211.2 million (Q3 2025), and $239.2 million (Q2 2025).